| 000 | 01649 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516154404.0 | ||
| 264 | 0 | _c20130917 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1521-7035 | ||
| 024 | 7 |
_a10.1016/j.clim.2013.05.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSethu, Swaminathan | |
| 245 | 0 | 0 |
_aImmunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. _h[electronic resource] |
| 260 |
_bClinical immunology (Orlando, Fla.) _cAug 2013 |
||
| 300 |
_a177-85 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aComplement Activation _xphysiology |
| 650 | 0 | 4 | _aCross Reactions |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xblood |
| 650 | 0 | 4 |
_aImmunologic Factors _ximmunology |
| 650 | 0 | 4 |
_aInterferon-beta _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aGovindappa, Karthik | |
| 700 | 1 | _aQuinn, Paul | |
| 700 | 1 | _aWadhwa, Meenu | |
| 700 | 1 | _aStebbings, Richard | |
| 700 | 1 | _aBoggild, Mike | |
| 700 | 1 | _aNaisbitt, Dean | |
| 700 | 1 | _aKimber, Ian | |
| 700 | 1 | _aPirmohamed, Munir | |
| 700 | 1 | _aPark, Kevin | |
| 700 | 1 | _aSathish, Jean | |
| 773 | 0 |
_tClinical immunology (Orlando, Fla.) _gvol. 148 _gno. 2 _gp. 177-85 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clim.2013.05.008 _zAvailable from publisher's website |
| 999 |
_c22839760 _d22839760 |
||